|
[1]
|
Jacob, T.C., Moss, S.J. and Jurd, R. (2008) GABAA Receptor Trafficking and Its Role in the Dynamic Modulation of Neuronal Inhibition. Nature Reviews Neuroscience, 9, 331-343. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Kilpatrick, G.J. (2021) Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. Frontiers in Pharma-cology, 12, Article ID: 690875. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Pesic, M., Stöhr, T., Ossig, J., et al. (2020) Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or without Alcohol: Results from Two Randomised Clinical Trials. Drugs in R & D, 20, 267-277. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Pesic, M., Schippers, F., Saunders, R., et al. (2020) Pharmaco-kinetics and Pharmacodynamics of Intranasal Remimazolam—A Randomized Controlled Clinical Trial. European Jour-nal of Clinical Pharmacology, 76, 1505-1516.
|
|
[5]
|
Antonik, L.J., Goldwater, D.R., Kilpatrick, G.J., et al. (2012) A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics. Anesthesia & Analgesia, 115, 274-283. [Google Scholar] [CrossRef]
|
|
[6]
|
Wiltshire, H.R., Kilpatrick, G.J., Tilbrook, G.S., et al. (2012) A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part II. Population Pharmacokinetic and Pharmacodynamic Mod-eling and Simulation. Anesthesia & Analgesia, 115, 284-296. [Google Scholar] [CrossRef]
|
|
[7]
|
Schüttler, J., Eisenried, A., Lerch, M., et al. (2020) Phar-macokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volun-teers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology, 132, 636-651.
|
|
[8]
|
Eisenried, A., Schüttler, J., Lerch, M., et al. (2020) Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Con-tinuous Infusion in Healthy Male Volunteers: Part II. Pharmacodynamics of Electroencephalogram Effects. Anesthesiol-ogy, 132, 652-666. [Google Scholar] [CrossRef]
|
|
[9]
|
Sthr, T., Colin, P.J., Ossig, J., et al. (2021) Pharmacokinetic Properties of Remimazolam in Subjects with Hepatic or Renal Impairment. BJA British Journal of Anaesthesia, 127, 415-423. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Zhou, J., Leonowens, C., Ivaturi, V.D., et al. (2020) Population Pharmacokinetic/Pharmacodynamic Modeling for Remimazolam in the Induction and Maintenance of General Anesthesia in Healthy Subjects and in Surgical Subjects. Journal of Clinical Anesthesia, 66, 109899.
|
|
[11]
|
Zhou, Y., Hu, P. and Jiang, J. (2017) Metabolite Characterization of a Novel Sedative Drug, Remimazo-lam in Human Plasma and Urine Using Ultra High-Performance Liquid Chromatography Coupled with Synapt High-Definition Mass Spectrometry. Journal of Pharmaceutical & Biomedical Analysis, 137, 78-83. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Morita, K., Takeda, J., Sakamoto, A., et al. (2020) Efficacy and Safety of Remimazolam versus Propofol for General Anesthesia: A Multicenter, Single-Blind, Randomized, Paral-lel-Group, Phase IIb/III Trial. Journal of Anesthesia, 34, 543-553. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Hirata, N., Suzuki, T., Morisaki, H., et al. (2020) Safety and Ef-ficacy of Remimazolam in Induction and Maintenance of General Anesthesia in High-Risk Surgical Patients (ASA Class III): Results of a Multicenter, Randomized, Double-Blind, Parallel-Group Comparative Trial. Journal of Anesthesia, 34, 491-501. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Kilpatrick, G.J., Mcintyre, M.S., Cox, R.F., et al. (2007) CNS 7056: A Novel Ultra-Short-Acting Benzodiazepine. Anesthesiology, 107, 60-66.
|
|
[15]
|
Chen, X., Sang, N., Song, K., et al. (2020) Psychomotor Recovery Following Remimazolam-Induced Sedation and the Effectiveness of Flumazenil as an Antidote. Clinical Therapeutics, 42, 614-624. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Worthington, M.T., Antonik, L.J., Goldwater, D.R., et al. (2013) A Phase Ib, Dose-Finding Study of Multiple Doses of Remimazolam (CNS 7056) in Volunteers Undergoing Colonoscopy. Anesthesia & Analgesia, 117, 1093-1100. [Google Scholar] [CrossRef]
|
|
[17]
|
Yoshida, A., Kurata, S., Kida, K., et al. (2021) Anesthetic Management for the Sleep-Awake-Sleep Technique of Awake Craniotomy Using a Novel Benzodiazepine Remimazolam and Its Antagonist Flumazenil. JA Clinical Reports, 7, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Masui, K. (2020) Remimazolam Besilate, a Benzodiazepine, Has Been Approved for General Anesthesia!! Journal of Anesthesia, 34, 479-482. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Wesolowski, A.M., Zaccagnino, M.P., Malapero, R.J., et al. (2016) Remimazolam: Pharmacologic Considerations and Clinical Role in Anesthesiology. Pharmacotherapy: The Jour-nal of Human Pharmacology and Drug Therapy, 36, 1021-1027. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Hu, K., Xiang, Q., Wang, Z., et al. (2020) Effects of Vitamin D Receptor, Cytochrome P450 3A, and Cytochrome P450 Oxi-doreductase Genetic Polymorphisms on the Pharmacokinetics of Remimazolam in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development, 10, 22-29.
|